FDA end-of-Phase 2 meeting with FDA
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Imsidolimb for Generalized Pustular Psoriasis (GPP) End-of-phase 2 meeting with FDA
Clinical Trial (NCT03619902) A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis (GPP)
WHAT IS THE NEXT CATALYST EVENT?
End-of-phase 2 meeting with FDA
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Updated by MV
imsidolimab, GPP, generalized pustular psoriasis, ANAB, skin disorder, skin disease
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post